Supplementary Figure S3 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy

Chand, Dhan; Savitsky, David A.; Krishnan, Shanmugarajan; Mednick, Gabriel; Delepine, Chloe; Garcia-Broncano, Pilar; Soh, Kah Teong; Wu, Wei; Wilkens, Margaret K.; Udartseva, Olga; Vincent, Sylvia; Joshi, Bishnu; Keith, Justin G.; Manrique, Mariana; Marques, Marilyn; Tanne, Antoine; Levey, Daniel L.; Han, Haiyong; Ng, Serina; Ridpath, Jackson; Huber, Olivia; Morin, Benjamin; Galand, Claire; Bourdelais, Sean; Gombos, Randi B.; Ward, Rebecca; Qin, Yu; Waight, Jeremy D.; Costa, Matthew R.; Sebastian-Yague, Alvaro; Rudqvist, Nils-Petter; Pupecka-Swider, Malgorzata; Venkatraman, Vignesh; Slee, Andrew; Patel, Jaymin M.; Grossman, Joseph E.; Wilson, Nicholas S.; Von Hoff, Daniel D.; Stebbing, Justin; Curiel, Tyler J.; Buell, Jennifer S.; O’Day, Steven J.; Stein, Robert B.

doi:10.1158/2159-8290.27938664

Supplementary Figure S3 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy

journal contribution

posted on 2024-12-02, 08:41 authored by Dhan Chand, David A. Savitsky, Shanmugarajan Krishnan, Gabriel Mednick, Chloe Delepine, Pilar Garcia-Broncano, Kah Teong Soh, Wei Wu, Margaret K. Wilkens, Olga Udartseva, Sylvia Vincent, Bishnu Joshi, Justin G. Keith, Mariana Manrique, Marilyn Marques, Antoine Tanne, Daniel L. Levey, Haiyong Han, Serina Ng, Jackson Ridpath, Olivia Huber, Benjamin Morin, Claire Galand, Sean Bourdelais, Randi B. Gombos, Rebecca Ward, Yu Qin, Jeremy D. Waight, Matthew R. Costa, Alvaro Sebastian-Yague, Nils-Petter Rudqvist, Malgorzata Pupecka-Swider, Vignesh Venkatraman, Andrew Slee, Jaymin M. Patel, Joseph E. Grossman, Nicholas S. Wilson, Daniel D. Von Hoff, Justin Stebbing, Tyler J. Curiel, Jennifer S. Buell, Steven J. O’Day, Robert B. Stein

This dataset presents comparative results demonstrating the enhanced T cell modulation in the tumor microenvironment promoted by Fc-enhanced anti-CTLA-4 versus the parental anti-CTLA-4 antibody in two specific tumor-bearing mouse models: MC38 and CT26. These data demonstrate the superior ability of Fc-enhanced anti-CTLA-4 to promote T cell infiltration and Treg depletion in the tumor microenvironment. This information is crucial for understanding the mechanistic basis for the improved anti-tumor efficacy of Fc-enhanced anti-CTLA-4 antibodies.

History

ARTICLE ABSTRACT

This study reveals that Fc-enhanced anti–CTLA-4 harnesses novel mechanisms to overcome the limitations of conventional anti–CTLA-4, effectively treating poorly immunogenic and treatment-refractory cancers. Our findings support the development of a new class of immuno-oncology agents, capable of extending clinical benefit to patients with cancers resistant to current immunotherapies.